ArticleThe Laryngoscope2021
Adjuvant Migraine Medications in the Treatment of Sudden Sensorineural Hearing Loss.
Article in The Laryngoscope, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05403229 (The Role of Migraine Prophylaxis Agent Topiramate in Treating Patients With Sudden Sensorineural Hearing Loss), which is not on this map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Role of Migraine Prophylaxis Agent Topiramate in Treating Patients With Sudden Sensorineural Hearing Loss
Who cites it
16 citing papers in PubMed, 25 citations in OpenAlex.
- Meniere's Disease and Migraine: Effect of Migraine Medications on Symptoms of Meniere's Disease.The Laryngoscope · 2026Article
- Migraine and auditory dysfunction: beyond comorbidity.Journal of neurology · 2026Review
- Pharmacotherapeutic Interventions for Sensorineural Hearing Loss: A Scoping Review.Audiology research · 2026Review
- Migraine Features in Patients With Sudden Sensorineural Hearing Loss.Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery · 2026Article
- Expanding the Spectrum of Central Sensitivity Syndrome: Integrating Otologic Migraine as Otologic Central Sensitivity Syndrome.Brain sciences · 2026Review
- Potential Benefits of Flunarizine in Patients with Sudden Sensorineural Hearing Loss with Incomplete Recovery Following Conventional Steroid Treatment: A Retrospective Analysis.Medicina (Kaunas, Lithuania) · 2025Article
- Beyond Vertigo: Vestibular, Aural, and Perceptual Symptoms in Vestibular Migraine.Current pain and headache reports · 2024Review
- White Matter Hyperintensity in Patients with Sudden Sensorineural Hearing Loss.Diagnostics (Basel, Switzerland) · 2024Article
- Google Trends Analysis of Otologic Symptom Searches Following COVID-19.Iranian journal of otorhinolaryngology · 2024Article
- Sudden Hearing Loss Waves: The Effect of COVID-19 Infection and Vaccination on the Inner Ear.Advances in experimental medicine and biology · 2024Review
- Migraine management for the otolaryngologist.Laryngoscope investigative otolaryngology · 2023Review
- Management of Migraine-Associated Vestibulocochlear Disorders.Audiology research · 2023Review
- A proposed association between subjective nonpulsatile tinnitus and migraine.World journal of otorhinolaryngology - head and neck surgery · 2023Review
- Repurposable Drugs That Interact with Steroid Responsive Gene Targets for Inner Ear Disease.Biomolecules · 2022Article
- Migrainous Vertigo, Tinnitus, and Ear Symptoms and Alternatives.Otolaryngologic clinics of North America · 2022Review
- Migraine and risk of sudden sensorineural hearing loss: A systematic review and meta-analysis.Laryngoscope investigative otolaryngology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
objectives/hypothesisTo examine the hearing outcomes of patients with sudden sensorineural hearing loss (SSNHL) treated with oral and intratympanic (IT) steroid only or a combination of steroid and migraine treatment. Our hypothesis was that adjuvant migraine medications may improve outcomes in SSNHL.
methodsA retrospective chart review at a tertiary otology center was conducted to identify patients with SSNHL who received oral steroid and IT dexamethasone injection(s) with or without migraine medications (a combination of nortriptyline and topiramate).
resultsA total of 47 patients received oral steroid and IT dexamethasone injection(s) only, and 46 patients received oral steroid and IT dexamethasone injection(s) as well as migraine lifestyle changes plus a combination of nortriptyline and topiramate. There were no significant differences in demographics and baseline audiometric data between the two groups. Both groups demonstrated improvements in pure tone average (PTA) and hearing thresholds at 250 Hz and 8000 Hz posttreatment. However, compared to steroid-only group, the adjuvant migraine medications group had significantly greater improvements in hearing thresholds at the lower frequencies (250 Hz, 500 Hz, 1000 Hz). Patients in the latter cohort also had greater improvement in PTA (P = .01) and received fewer IT injections (P = .04) PTA improvement of ≥ 10 dB was observed in 36 patients (78%) in the adjuvant migraine medications group and 22 patients (46%) in the control group (P < .001).
conclusionIn multimodal treatment of SSNHL, supplementing oral and IT steroid with migraine medications may result in greater improvements in lower frequency hearing thresholds and PTA. Furthermore, adjuvant migraine treatment can lead to decrease in number of IT injections, thus reducing procedure-related risks and complications. LEVEL OF EVIDENCE: 3 Laryngoscope, 131:E283-E288, 2021.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.